Under a tenth of patients that would benefit from GLP-1 drugs such as Wegovy can access them, caution the global health agency as it publishes its inaugural guidance on the medications.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for more widespread and fairer access to these injectable treatments.
Based on estimates, over two billion could be obese by 2030 unless action is taken.
"Our new guidance affirms that obesity is a long-term condition that can be addressed with holistic and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key obstacles to widespread access to the treatments that can assist patients in reducing substantial weight, notes the organization.
Skinny Jab Supply Crisis
Even under the current most favorable outlook, the supply of these medications would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the health organization.
The guideline encourages countries and companies to expand availability, through strategies like voluntary licensing.
The intellectual property rights on a key compound – the primary component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Function
GLP-1 drugs imitate a natural hormone to delay gastric emptying, curb appetite and enhance satiety so individuals reduce food intake.
People commonly see weight reduction after several weeks of beginning the regular doses.
Studies points to patients may regain a significant portion within a year of discontinuing the treatment, because their normal appetite come back.
To be carrying excess weight raises your risk for developing diseases, including diabetes, heart disease, stroke, and specific malignancies.
Excess weight affects people in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, as per the health agency.
